ABEO · Abeona Therapeutics Inc

-

Please sign in to comment on ABEO

1 Comment

Admin

3 years, 7 months ago

Abeona Therapeutics Inc is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.

From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.1.

Abeona Therapeutics Inc's total revenue rose by inf% to $3M since the same quarter in the previous year.

Its net income has increased by 3.7% to $-16M since the same quarter in the previous year.

Finally, its free cash flow grew by 88.6% to $-2M since the same quarter in the previous year.

Based on the above factors, Abeona Therapeutics Inc gets an overall score of 4/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	US00289Y1073
CurrencyCode	USD
Exchange	NASDAQ

Dividend Yield	0.0%
Beta	1.19
Market Cap	52M
Target Price	29
PE Ratio	None

ABOUT

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

ABEO · Abeona Therapeutics Inc

-

Abeona Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Abeona Therapeutics Inc using a moving average strategy